Kyle J. Seamon

Pancreatic cancer

Split crRNA with CRISPR-Cas12a enabling highly sensitive and multiplexed detection of RNA and DNA

Direct targeting of RAS in pancreatic ductal adenocarcinoma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RAS^MULTI(ON) inhibitor.

Use of anti-CRISPR protein AcrIIA4 as a capture ligand for CRISPR/Cas9 detection